Valproic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Valproic Acid: From Epilepsy to Trigeminal Nerve Neoplasm
One-Sentence Summary
Valproic acid (VPA) is a broad-spectrum antiepileptic and mood-stabilizing agent, classically used internationally for epilepsy, bipolar disorder, and migraine prevention, though it currently holds no registered approval in India. The TxGNN model predicts it may be effective for Trigeminal Nerve Neoplasm, with 0 clinical trials and 1 publication currently available to support this direction. The evidence base for this specific indication is minimal, placing this prediction at a purely exploratory stage without clinical validation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No India registration; internationally indicated for epilepsy, bipolar disorder, and migraine prevention |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the provided Evidence Pack. Based on known pharmacological information, Valproic acid is a well-established antiepileptic drug that — beyond its anticonvulsant properties — also inhibits histone deacetylases (HDACs). This HDAC inhibitory activity has attracted considerable interest in oncology research, as it can theoretically reactivate silenced tumor suppressor genes, impair cell cycle progression, and induce apoptosis and differentiation in neoplastic cells.
However, the link between VPA and trigeminal nerve neoplasm specifically is not well-supported at this time. While VPA’s HDAC inhibitory activity provides a theoretical antineoplastic mechanism applicable across multiple tumor types, there is no established disease-specific pathway connecting it to tumors of the trigeminal nerve. The high TxGNN score (99.97%) most likely reflects VPA’s broad connectivity in the knowledge graph with general neurological and neural tumor nodes, rather than a validated indication-specific pathway.
The sole available literature reference (PMID 9157801) is a Sturge-Weber syndrome case series in which VPA was employed for seizure control — not as an antineoplastic agent — and carries no direct relevance to trigeminal nerve neoplasm treatment. This gap significantly limits confidence in the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9157801 | 1997 | Case series | Anales espanoles de pediatria | Review of 14 Sturge-Weber syndrome patients over 25 years; VPA used exclusively for seizure control, not as antineoplastic therapy — no direct relevance to trigeminal nerve neoplasm |
India Market Information
Valproic acid is currently not registered in India. No license or approval records are available.
Safety Considerations
Drug Interactions (248 total interactions identified; selected key interactions shown below):
| Interacting Drug | Severity | Clinical Note |
|---|---|---|
| Glycerol phenylbutyrate | Major | Clinically significant — avoid combination |
| Bupropion | Moderate | Monitor for increased seizure risk |
| Morphine | Moderate | Monitor for CNS depression potentiation |
| Morphine (liposomal) | Moderate | Monitor for CNS depression potentiation |
| Acetylsalicylic acid | Moderate | May displace VPA from protein binding; monitor levels |
| Clarithromycin | Moderate | May inhibit VPA metabolism; monitor drug levels |
| Activated charcoal | Moderate | Reduces VPA absorption if co-administered |
| Difenoxin | Moderate | Monitor for enhanced CNS effects |
| Diphenoxylate | Moderate | Monitor for enhanced CNS effects |
| Dronabinol | Moderate | Monitor for additive CNS depression |
| Metoclopramide | Moderate | Monitor for altered VPA pharmacokinetics |
| Nabilone | Moderate | Monitor for additive CNS depression |
| Cimetidine | Minor | May slightly elevate VPA levels |
| Aluminum/Magnesium/Calcium antacids | Minor | Minimal effect; separate dosing if possible |
Please refer to the package insert for complete warnings, contraindications, and hepatotoxicity/teratogenicity black-box warnings known to be associated with valproic acid.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite the TxGNN model’s high prediction score (99.97%), there is no supporting clinical trial evidence and the sole literature reference has no direct relevance to trigeminal nerve neoplasm treatment. This is a purely model-driven prediction (L5) and cannot advance to clinical consideration without foundational preclinical evidence.
To proceed, the following is needed:
- Preclinical studies (in vitro or in vivo) specifically examining VPA’s effect on trigeminal nerve neoplasm cell lines or animal models
- Confirmation that HDAC-inhibitory plasma concentrations of VPA are achievable at trigeminal nerve tumor sites
- At least one case report or case series documenting VPA use in trigeminal nerve neoplasm patients
- Full MOA data retrieved from DrugBank to evaluate mechanistic specificity
- CDSCO package insert review to characterize India-relevant safety profile, warnings, and contraindications
- India regulatory pathway assessment before any clinical study design
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.